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Abstract.  Diphtheria toxin (DT)  receptor associates 
with a  27-kD membrane protein (DRAP27)  in monkey 
Vero cells. A  cDNA encoding DRAP27 was isolated, 
and its nucleotide sequence was determined. The de- 
duced amino acid sequence revealed that DRAP27 
is the monkey homologue of human CD9 antigen. 
DRAP27  is recognized by CD9 antibodies. A  human- 
mouse hybrid cell line (3279-10)  possessing human 
chromosome 5,  sensitive to DT, but not expressing 
CD9 antigen, was used for transfection experiments 
with DRAP27.  When the cloned cDNA encoding 
DRAP27  was transiently expressed in 3279-10  cells, 
the total DT binding capacity was three to four times 
higher than that of untransfected controls. Transfec- 
tants stably expressing DRAP27 have an increased 
number of DT binding sites on the cell surface. Fur- 
thermore, the transfectants are 3-25  times more sensi- 
tive to DT than untransfected cells, and the sensitivity 
of these cells to DT is correlated with the number of 
DRAP27 molecules on the surface. However, when 
the cloned cDNA was introduced into mouse cell lines 
that do not express DT receptors,  neither an increased 
DT binding nor enhancement of DT sensitivity was 
observed.  Hence, we conclude that DRAP27 itself 
does not bind DT, but serves to increase DT binding 
and consequently enhances DT sensitivity of cells that 
have DT receptors.  12 proteins related to DRAP27/ 
CD9 antigen were found through homology search 
analysis. These proteins appear to belong to a  new 
family of transmembrane proteins. 
IPHTHERIA toxin  (DT), ~ secreted  by  Corynebac- 
terium diphtheriae, is  a  cytotoxic protein  (Mr  = 
58,342)  that inhibits cellular protein synthesis in eu- 
karyotes by inactivating elongation factor 2 through ADP ri- 
bosylation (for reviews, see references 18 and 48). Entry of 
the toxin, or at least the A fragment, into the cytoplasm is 
required for the cytotoxic action to occur (65).  The toxin 
binds to a specific receptor on the cell surface (15, 37) and 
is then internalized by receptor-mediated endocytosis (42, 
45).  A conformational change of the toxin molecule takes 
place in an acidic compartment, resulting in the interaction 
of hydrophobic domains of the toxin molecule with the lipid 
bilayer of the compartment (10, 11, 14, 52).  Finally, the en- 
zymatically active A fragment is translocated to the cytosol 
(43, 44), where it inactivates elongation factor 2. The sensi- 
tivity of cells to DT varies among species. Cells from many 
mammals, including humans and monkeys, are sensitive to 
1. Abbreviations  used in this paper:  DRAP27, 27-kD  diphtheria toxin re- 
ceptor-associated protein; DT, diphtheria toxin; RDS, retinal degeneration 
slow proteins. 
DT, but those from rats and mice are not (40). The difference 
in DT sensitivity among cells is primarily determined by the 
number of DT-specific receptors on the surface (31, 36, 41). 
The Vero cell line, derived from monkey kidney, is one of 
the cell lines most sensitive to DT (40). The use of Vero cells 
has  facilitated  biochemical  studies  of  the  DT  receptor. 
Chemical cross-linking of the protein(s) on the cell surface 
with DT followed by immunoprecipitation with anti-DT anti- 
body indicated that a  10-20-kD  membrane protein  from 
Vero cells was a candidate for the DT receptor (15).  Using 
a solubilized fraction of  Vero cell membrane, we showed that 
a 14.5-kD membrane protein (DTR14.5)  is the DT receptor, 
or at least the binding moiety (37).  In subsequent studies, 
DTR14.5 was purified (38).  Furthermore, it was shown that 
DTR14.5  forms a complex or associates with another pro- 
tein.  In gel filtration studies of the solubilized membrane 
fraction, DT receptor eluted in fractions corresponding to a 
larger than expected size (37, 38). Additional evidence came 
from studies using a mAb that inhibits the binding of DT to 
Veto cells (28).  This mAb, called 007, does not recognize 
DTR14.5  itself,  but  rather  a  27-kD  membrane  protein. 
Studies using mAb 007 showed that this 27-kD  membrane 
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correlation was found between the sensitivity of a cell line 
to DT and the number of DRAP27  molecules on the cell 
surface. 
We  describe  here  the  cloning  of the  cDNA  encoding 
DRAP27. The nucleotide sequence data and other evidence 
show that DRAP27 is the monkey homologue of human CD9 
(cluster of differentiation)  antigen.  Transfection experiments 
using the cloned cDNA indicate that DRAP27 indeed plays 
a role in the binding of DT to cells and the sensitivity to DT. 
Moreover,  homology  search  analysis  indicates  that  the 
DRAP27/CD9 antigen belongs to a new family of transmem- 
brahe proteins. 
Materials and Methods 
Enzymes and Chemicals 
Restriction  enzymes and other enzymes for DNA manipulation were pur- 
chased from Toyobo Co., Ltd.  (Osaka, Japan). A cDNA synthesis kit was 
purchased from Amersham Corp.  (Arlington Heights,  IL).  [a-32p]dCTP 
and [1251]Nal were from New England Nuclear (Boston, MA). 
Antibodies 
mAb 007 was produced and purified in our laboratory as described previ- 
ously (28).  Mouse CD9 mAbs ALB6, BU16, MAB1206,  and TP82 were 
purchased from Nichitei Co., Ltd. (Tokyo, Japan), The Binding Site, Inc. 
(San Diego, CA), Chemical International Inc.  (Temecula,  CA), and MBL 
Co., Ltd. (Nagoya, Japan), respectively. Affinity-purified goat anti-mouse 
IgG, FITC-conjngated goat anti-mouse IgG, and HRP-conjugated goat anti- 
mouse IgG were from Zymed Laboratories,  Inc. (South San Francisco, CA). 
Preparation of the cDNA Library 
Total  RNA  from monkey  Veto  cells was  prepared by the SDS/phenol 
method and poly(A)  + RNA was purified by oligo (dT)-cellulose chroma- 
tography (51). Douhle-stranded DNA was prepared from 5 #g poly(A)  + 
RNA  using a  cDNA  synthesis kit.  The cDNAs were ligated to  8-  (5' 
CTGGAAAG)  and 12-met (5' CTTTCCAGCACA) phosphorylated BstXI 
linkers (2). Excess linkers and cDNAs of <200 bp were removed using a 
Select-6L spin column from 5 Prime 3 Prime, Inc. (West Chester, PA). The 
size-fractionated  cDNAs were then ligated into the CDM8 expression vec- 
tor (56), which had been digested with BstXI and recovered  from a low- 
melting-point agarose gel. Finally,  the ligation mixtures were introduced 
into Escherichia coil MC1061/p3, resulting in 1 ￿  10  ~ independent clones. 
DNA Preparation 
Pools of colonies were cultured on LB agar plates.  Plasmid DNA was iso- 
lated by the alkaline lysis method and purified either by CsCl-ethidium bro- 
mide gradient centrifugation or by phenol/chloroform extraction and etha- 
nol precipitation (51). 
Screening of the Transfectant of COPS Cells 
Folyoma virus-transformed murine COPS cells were used for screening of 
the eDNA library.  Plasmid DNA was introduced into COPS cells by the 
DEAE-dextran method, with chloroquine  treatment (6). 48 h after transfec- 
tion, COPS cells were washed once with binding medium (MEM-NEAA 
supplemented with 10% bovine calf serum and 20 mM Hepes, pH 7.2), in- 
cubated with mAb 007 at 250 ng/ml in binding medium at 370C for 1 h, 
washed twice with washing buffer (PBS supplemented with 0.5 mM CaC12, 
0.5 mM MgC12, and 1 mg/ml BSA), and once with binding medium. Then 
the cells were further incubated at 370C for 1 h with ~2SI-labeled  goat anti- 
mouse IgG at 500 ng/mi in binding medium containing 2 % goat serum. 
Goat anti-mouse IgG was labeled with 12sI using Enzymobeads (Bio-Rad 
Laboratories, Richmond, CA) as described previously (28). The labeled an- 
tibody had a specific activity of 1.1-1.3 ￿  104 cpm/ng protein. Binding of 
the radiolabeled antibody was measured either by autoradiography or by di- 
rect counting with a  .y-counter.  For autoradiography,  transfeetants were 
washed twice with washing buffer and once with PBS supplemented with 
0.5 mM CaCI2 and 0.5 mM MgC12, fixed with PBS containing 2% formal- 
dehyde at ambient temperature for 1 h, and dried. The edge of the dish was 
cut off, and the flat portion was attached to x-ray film. The film was exposed 
with an intensifying screen for several days at -20oC and then developed. 
For counting with a ~,-counter, transfectants  were washed twice with wash- 
ing buffer  and once with binding medium, they were  lysed  with 0.1  N 
NaOH,  and the radioactivity of the lysate was counted. 
Western Blotting 
Cells transfected with plasmid were detached from the plates with PBS con- 
taining 0.02 % azide and 1 mM EDTA and then pelleted by centrifugation. 
The pellets were suspended in SDS gel sample buffer without reducing agent 
and boiled for 2 min. The samples were run on 12.5% SDS-PAGE and then 
transferred to a nitrocellulose filter (S&S BAS 85) by etectrotransfer.  The 
filter was blocked with TBS (20 mM Tris-HC1, pH 7.5, 0.1 M NaC1) con- 
taming 3 % nonfat milk at 37~  for 1 h and then incubated with 5 #g/ml 
mAb 007 in TBS buffer and 1% nonfat milk at 4oC for 14 h. The filter was 
washed  three times with TTBS (20 mM Tris-HCl, pH 7.5, 0.1 M  NaCl, 
0.05%  Tween 20) at ambient temperature for 15 min and then incubated 
with HRP-conjugated  goat anti-mouse IgG (diluted 1:2,000) in TBS with 
1% nonfat milk at 37~  for 2 h, followed by three washes with TTBS.  Fi- 
nally, the filter was developed in 0.05 % DAB in 50 mM Tris-HCl,  pH 7.4, 
containing 0.03%  H202. 
Immunofluorescence Microscopy 
Cells transfected with ptasmid were detached from dishes and replated on 
cover slips. The cells on the cover slips were incubated with 100 #g/ml mAb 
007 in binding medium at 4~  for 3 h. The cells were washed with washing 
buffer, incubated at 37~  for 2 h in FITC-conjugated  goat anti-mouse anti- 
body (diluted  1:2,000)  in binding medium, and washed three times with 
washing buffer. The cover slips were mounted on a glass slide and observed 
under a fluorescence  microscope. 
DNA Sequencing 
Both strands of the single clone pCT1843 were sequenced  by the dideoxy- 
mediated chain termination method (54) after successive deletion by exonu- 
clease  Bal31 and subcloning into pUC18. 
Stable Expression of  DRAP27 in Human-Mouse 
Hybrid 3279-10 Cells 
Human-mouse hybrid 327940 cells were grown in DME supplemented 
with 10% FBS and 300 t~g/m113418. To isolate stable transfectants express- 
ing  DRAP27,  ,'o106 3279-10  cells  were  cotransfected  with  11  t~g  of 
pCT1843 and 3 ~g of HSV-TK gene (pHSV106) using DEAE-dextran as de- 
scribed above. After 48 h, the medium was replaced with HAT medium sup- 
plemented with 300 ~g/ml G418 (selection medium). Cells were then cul- 
tured for 7  d.  Colonies growing  in selection medium were picked and 
subjected to immunofluorescence  staining to test the expression of DRAP27 
on the surface  of the cells.  Colonies were subcloned until almost all cells 
from each colony  were positive for DRAP27. 
Assay for DT Cytotoxicity 
The sensitivity of cells to DT was assayed by measuring the inhibition of 
protein synthesis by DT as described previously (36).  In this study, cells 
(1  x  105) were seeded in 24-well trays and incubated for 16 h. Then cells 
were incubated with DT for 4 h at 37~  followed by incubation in the pres- 
ence of [3H]leucine (2/~Ci/ml) for 60 rain. The radioactivity incorporated 
into ~-A-insoluble material was measured. 
Assay for the Binding of CRMI97 
CRM197 was labeled with Nal2SI using Enzymobeads.  The specific activ- 
ity of the CRM197  used for this assay was  1.5-2.5  ￿  104 cpm/ng. Cells 
were seeded in multiwell  trays and incubated for 16 h in a CO2 chamber. 
Then the medium was replaced  with binding medium. 125I-CRM197 was 
added and the cells were incubated at 4~  for 6 h or for the times indicated. 
The cells were  washed,  lysed,  and the cell-associated radioactivity  was 
counted as described previously (35). Nonspecific binding of 125I-CRM197 
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binding was determined  by subtracting  the nonspecific  binding from  the to- 
tal binding obtained with ~2sI-CRM197 alone. 
Results 
Isolation of  cDNA for DRAP27 
Binding  studies  using  ~25I-labeled anti-DRAP27  antibody 
007 showed that monkey Vero cells express DRAP27 abun- 
dantly (28). To isolate the cDNA encoding DRAP27, we syn- 
thesized double-stranded cDNAs from mRNA of Vero cells 
and introduced them into the expression vector CDM8 (56). 
The cDNA library was divided into 10 pools of ~10,000 in- 
dependent clones. The cDNAS in each pool were introduced 
into murine COPS cells and the cells were cultured for 48 h. 
The cells were incubated with mAb 007 followed by incuba- 
tion with zzSI-labeled anti-mouse IgG, then subjected to au- 
toradiography. One pool of the cDNA library that showed a 
positive  signal  was  further  divided  into  smaller  groups, 
and these were introduced into COPS cells.  Groups were 
screened by direct counting using a ~-counter. This proce- 
dure was repeated until a single clone was obtained, and the 
recombinant plasmid from this clone was named pCT1843. 
To confirm that the cloned cDNA in pCT1843  encodes 
DRAP27,  cell  lysate  of  COPS  cells  transfected  with 
pCT1843 was analyzed by Western blotting.  Transfectants 
harboring pCT1843 showed a distinct band at 27 kD, which 
was identical to DRAP27 from Vero cell membrane. Neither 
mock transfectants nor cells transfected with CDM8 showed 
any band at all (data not shown). In addition, immunofluo- 
rescence staining showed that the 27-kD protein was local- 
ized on the surface of COPS cells transfected with pCT1843. 
These data  indicate  that  pCT1843  encodes  the  complete 
structural gene lor DRAP27. 
DRAP27 Is the Monkey Homologue 
of  Human CD9 Antigen 
The nucleotide sequence of the  1,120-bp  cDNA  insert in 
pCT1843 was determined (data not shown;  sequence data 
are available from EMBL/GenBank/DDBJ under accession 
number D10726). Only one open reading frame encoding a 
228-amino acid protein (Mr =  25,868) was found. The nu- 
cleotide sequence from positions -3 to +4 is similar to the 
consensus sequence for initiation of translation (32). Homol- 
ogy search analysis revealed that the deduced amino acid se- 
quence of DRAP27 differs at only two residues from human 
CD9 antigen (34). ASp-151 and I1e-178 in DRAP27 are re- 
placed by Asn-151 and Vai-178, respectively, in CD9 antigen 
(see Fig. 7). 
A number of mAbs to CD9 antigen have been isolated (13, 
58).  We  examined  whether  CD9  antibodies  react  with 
DRAP27.  Cell  lysates  of  COPS  cells  transfected  with 
pCT1843 were subjected to Western blotting using a mouse 
anti-CD9 mAb, ALB6, as probe. The antibody showed a dis- 
tinct band identical to DRAP27 (data not shown). We then 
tested whether anti-CD9  mAbs  inhibit the binding of DT 
to Vero cells, as does the anti-DRAP27 antibody 007. Sur- 
prisingly,  all  four  mouse  mAbs  to  CD9  (ALB6,  BU16, 
MAB1206, and TP82) inhibited the binding of CRM197 to 
Vero cells. Fig.  1 shows the inhibitory effect of ALB6 and 
TP82. Although the epitopes recognized by these antibodies 
are not characterized, the antibodies used were isolated in- 
dependently. From these results, we conclude that DRAP27 
is the monkey homologue of human CD9 antigen. 
Inhibition of  DT Toxicity by Antibody 007 Is Mediated 
by CD9 Antigen 
We previously showed that the mAb 007 binds to various hu- 
man cell lines (28). As shown in Fig. 2, antibody 007 inhibits 
the toxicity of DT to human HEL and FL cells. These results 
indicate that antibody 007 reacts with human CD9 antigen 
and suggest that human CD9 antigen also participates in DT 
intoxication. 
The gene encoding CD9 antigen is located on human chro- 
mosome 12 (9), whereas the gene responsible for DT sensi- 
tivity, probably the gene for the DT receptor, is located on 
human chromosome 5  (20).  The 3279-10 cell line,  a hu- 
man-mouse hybrid, contains only human chromosomes 5 
and 22 (24), and thus should not express CD9 antigen. We 
confirmed by immunofluorescence staining that this cell line 
does not express CD9 antigen. As shown in Fig. 2, antibody 
007 does not inhibit the toxicity of DT for 3279-10 cells. This 
result is consistent with the hypothesis that the inhibitory 
effect of antibody 007 is mediated by the binding of the anti- 
body to DRAP27/CD9 antigen, which these cells lack. 
Transfection of  cDNA Encoding 
DRAP27 Enhances the Binding of  DT to CD9 
Antigen-negative Hybrid Cells 
To study the role of DRAP27/CD9 antigen in DT binding 
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Figure 1. Inhibition of ~25I-labeled CRM197 binding to Vero cells 
by anti-CD9 monoclonal antibodies. Vero cells were incubated with 
various amounts of each antibody at 4~  for 2 h.  125I-Labeled 
CRM197 (55 ng/ml) was added, and the cells were further incu- 
bated at 4~  for 4 h. The cells were washed, and the cell-associated 
radioactivity was counted. The results are expressed as percent of 
specific binding in the absence of antibody. ([]) anti-CD9 mono- 
clonal antibody ALB6; (o) TP82; (e) anti-DRAP27 antibody 007. 
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Figure 2.  Effect  of anti-DRAP27 monoclonal antibody 007 on the 
toxicity of DT for human FL cells, HEL cells, and human-mouse 
hybrid 3279-10 cells. Various concentrations of antibody 007 were 
added  to cultures  of FL cells  (I), HEL cells  (*), and  3279-10 
cells (e), and the cells were incubated at 37~  for 30 min. DT was 
added (5 ng/ml for HEL cells,  10 ng/ml for FL cells, and 3279-10 
cells). The cells were further incubated for 2 h (FL cells and HEL 
cells) or 4 h (3279-10 cells), followed by incubation with 2 #Ci/ml 
of [3H]leucine for  60  min.  The  radioactivity  incorporated  into 
protein was measured. The data are expressed as percent of incor- 
poration  in the absence of toxin. 
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Figure 3.  Increased  binding  of 125I-labeled CRM197 to human- 
mouse hybrid 3279-10 cells transfected with the cDNA encoding 
DRAP27. 48 h after transfection, cells were incubated at 4~  for 
6  h  with  the  indicated  concentrations  of ~25I-labeled CRM197. 
Cells were then washed, and the radioactivity associated with the 
cells was counted. The data are expressed as specific binding. The 
values for nonspecific binding of ~2SI-laheled CRM197 at 60 and 
120 ng/ml were '~2 X 10  -17 mol/105 cells and ,x,4 ￿  10  -17 mol/105 
cells,  respectively.  The  mean  values  of duplicate  samples  are 
plotted in this figure. Bars indicate the deviation of the individual 
values from the mean: open bars, mock transfection; dotted bars, 
CDM8 vector;  hatched bars, pCT1843. 
more directly, pCTI843  was introduced  into  cells lacking 
DRAP27/CD9  antigen,  and the binding activity was mea- 
sured. The binding studies were carried out using CRM197, 
a mutant form of DT, because of its advantages for binding 
studies,  as described previously (35,  37,  38). 
COPS cells and L  cells derived from mice have no DT 
receptors,  thus  no  specific binding of '25I-CRM197  is ob- 
served. We introduced pCTI843 into L cells or COPS cells. 
Binding  of l~q-CRM197  to the cells was tested 48 h  after 
introduction of the plasmid. Although immunofluorescence 
staining showed strong expression of DRAP27 on 20-30% 
of the  cells,  no  specific binding  of '25I-CRM197  was  ob- 
served in either cell line (data not shown). This result is con- 
sistent with our observation that the DRAP27 molecule itself 
is not the DT-binding molecule (28). 
Next, transfection experiments were performed using the 
human-mouse hybrid cell line,  3279-10.  Because monkey 
and  human  cells  express  large  amounts  of  endogenous 
DRAP27/CD9  antigen (28),  it may be difficult to examine 
the effect of the expression of the cDNA encoding DRAP27 
in such cells. The hybrid cell 3279-10 has DT receptors but 
does not express CD9 antigen.  Thus, we used the 3279-10 
cells as recipients in transfection experiments. As shown in 
Fig. 3, transfection of 3279-10 cells with pCT1843 increased 
specific binding  of CRM197  three-  to  fourfold compared 
with untransfected control cells.  Neither mock transfection 
nor transfection with the vector CDM8 had any effect. The 
transfection  efficiency  in  this  experiment  was  20-30%, 
judged by expression of DRAP27 on the cell surface by im- 
munofluorescence staining.  This suggests that,  in the cells 
expressing DRAP27,  the specific binding of CRM197  may 
have been enhanced by about  10-fold. 
Increased Sensitivity to DT in 3279-10 Cells 
Stably Expressing DRAP27 
To assess the role of DRAP27/CD9 antigen more precisely, 
stable  transfectants  of 3279-10  cells  expressing  DRAP27 
were isolated. Because 3279-10 cells already possess a neo- 
mycin resistance marker but lack the gene for thymidine ki- 
nase (24),  3279-10 cells were cotransfected with pCTl843 
and pHSV106 plasmid.  Colonies grown  in  HAT selection 
medium were tested for surface expression of DRAP27 by 
immunofluorescence staining, and several clones were iso- 
lated. 
The sensitivity of each clone to DT was tested. The results 
are shown in Fig. 4. The parental 3279-10 cells were sensi- 
tive to DT,  hut their sensitivity is ~60 times less than that 
of monkey Vero cells when EDs0 values are compared. Al- 
though the sensitivity differed from clone to clone,  all the 
clones expressing DRAP27 showed increased sensitivity to 
DT:  clones  C15-2,  C-l,  and C7-3  were 22,  6,  and 3 times 
more  sensitive  than  3279-10  cells,  respectively.  A  stable 
clone  of  3279-10  cells  transfected  with  pHSV106  alone 
showed no increase in DT sensitivity (data not shown). Fur- 
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Figure 4. Inhibition of protein synthesis 
by DT in stable transfectants of 3279-10 
cells  expressing  DRAP27,  parental 
3279-10  ceils, and monkey Vero cells. 
Cells were  incubated for 4  h  at 37~ 
with various concentrations of DT, fol- 
lowed  by  incubation  with  [3H]leucine 
for I h.  The radioactivity incorporated 
in proteins were measured as described 
in Materials and Methods. Data are ex- 
pressed as percent of protein synthesis 
for control without toxin. (e) clone C15-2 
cells;  (A)  clone  C-1  cells;  (A)  clone 
C7-3  cells; (=) parental 3279-10  cells; 
(o) Vero cells. 
thermore, the increased sensitivity to DT of clone C-1 was 
diminished by the addition of antibody 007, whereas the anti- 
body did not affect the DT sensitivity of the parental 3279-10 
cells (Fig. 5). 
The number of DRAP27 molecules on the surface of each 
transfectant clone was determined by measuring the binding 
of  ~2~I-labeled antibody  007  to  the  cells.  DT  sensitivity, 
number of DT binding sites, and their Ka values are shown 
in Table I. The sensitivity of cells to DT, the number of DT 
binding sites, and the number of DRAP27 molecules on the 
surface of cells are correlated. 
Transfection of mouse L  cells and COPS  cells with the 
cDNA of DRAP27 had no effect on the DT binding of these 
cells. We also examined the effect of expression of DRAP27 
on the sensitivity of L cells to DT.  To do this, we isolated 
stable transfectants of L  cells expressing DRAP27 by the 
same procedures used with 3279-10 cells. L cells are •4,400 
times less sensitive to DT than 3279-10 cells. Although clone 
LC-14 expressed DRAP27  in  amounts comparable to the 
transfectants of 3279-10 cells, the sensitivity to DT of these 
cells was similar to that of the parental L cells (Table I), indi- 
cating that the expression of DRAP27 in the absence of DT 
receptor does not enhance the sensitivity of cells. 
DRAP27 Increases the Number of  DT Receptors on 
the Surface of 3279-10 Cells 
In transient expression experiments, DRAP27 enhanced DT 
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Figure 5.  Effect of antibody 007 on the 
toxicity of DT for clone C-1 and 3279-10 
cells. Cells were incubated at 37~  for 
4 h with DT in the presence or absence 
of antibody 007,  and the inhibition of 
protein synthesis by DT was measured. 
The  data  are  expressed as  percent of 
protein synthesis in the control (without 
DT). C-1 cells, (o) no antibody, (zx) 10 
/zg/ml antibody, and (s) 30 #g/ml anti- 
body 007;  3279-10  cells, (o)  no anti- 
body 007,  (e) 30 #g/ml antibody 007. 
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Cells  DRAP27 expression*  DT sensitivity*  CRM197 binding  Ka 
molecules~cell  ng/ml  sites~cell 
3279-10  0  14.5  500 
C7-3  2.5  )<  106  5.6  1,300 
C-1  4.7  ￿  106  2.3  1,900 
C15-2  1.2  x  107  0.65  2,600 
Vero  5.6  x  106  0.23  19,500 
L  0  6.4  x  104  ND 
LC-14  4.7  ￿  106  5.5  ￿  104  ND 
0.6  ￿  109 
1.3  ￿  109 
1.0  x  109 
ND 
ND 
* Numbers of DRAP'27 molecules on the cell surface were determined by binding experiments with a saturating amount (100 #g/ml) of ~2SI-labeled antibody 007 
at 4"C for 6 h. 
* DT sensitivity was determined from the data of Fig. 4. The values are expressed as the concentration of toxin required to reduce the rate of protein synthesis 
to 50%  of the control value (EDs0). 
binding of 3279-10 cells. To examine the effect of DRAP27 
on DT binding more closely, binding of ~2SI-labeled CRM197 
to stable transfectants was measured.  As shown in Fig.  6, 
specific binding  is enhanced in the transfectants over the 
entire concentration range tested.  Specific binding of ~25I- 
labeled CRM197 to clones C15-2 and C-1 was ~5 and ~2.5 
times higher, respectively, than that in 3279-10 cells. Non- 
specific binding was not affected by the expression of DRAP27. 
Scatchard plot analysis indicated that C15-2 cells have 2,600 
sites/cell with a Ka of 1.3  x  109 M -l, while C-1 cells have 
1,900 sites/cell with a Ka of 0.6  ￿  109 M -2 (Fig. 6 B and Ta- 
ble I). The values for Vero cells, which were determined at 
the same time, were 19,500 sites/cell and 1.0 ￿  109 M -t (Ta- 
ble I). In the case of  parental 3279-10 cells, nonspecific bind- 
ing accounted for ~50% of the total binding; the data was 
not suited for Scatchard plot analysis, but we estimated the 
binding site number "~500 sites/cell. 
Antigen Belongs to a New Family of 
Transmembrane Proteins 
Proteins whose amino acid sequences showed significant ho- 
mology (a SD >6 using the method of Pearson and Lipman 
[49]) to DRAP27 were screened from data banks. Eight pro- 
teins besides CD9 antigen showed significant homology to 
DRAP27. Proteins showing homology to DRAP27, includ- 
ing CD9 antigen, are shown in Table II. These proteins in- 
clude TAPA-1, a target of antiproliferation antibody (47); CO- 
029, a human tumor-associated antigen (59); ME491/CD63 
antigen, a human melanoma-associated antigen (4, 5, 27, 39); 
Sm23 and Sj23 (23-kD antigens ofSchistosoma  mansoni and 
Schistosomajaponica, respectively [21, 67]); CD37 and CD53 
antigens, human leukocyte surface antigens (I,  16,  17, 55); 
and OX-44, a rat leukocyte antigen (8). The same screening 
mentioned above was performed again using the amino acid 
sequences of each of the nine proteins as a probe. Four addi- 
tional sequences showed significant homology only to ME491/ 
CD63 antigen. These proteins were normal human, bovine, 
mouse, and rat gene products corresponding to retinal de- 
generation slow (RDS) mutants (7,  19, 62, 63). 
Alignment of the amino acid sequences of the proteins 
listed in Table II using the maximum parsimony method of 
Hein (25) is shown in Fig. 7. Because the RDS proteins did 
not show significant homology to any of the proteins other 
than MFA91/CD63 antigen, RDS proteins are not listed in 
Fig. 7. The following structural similarities are found in all 
the proteins in Fig. 7, suggesting that they have the same to- 
pology in the membrane:  (a)  they contain three putative 
transmembrane  domains  in  the  NH2-terminal  portion,  a 
long hydrophilic (or amphiphasic) domain, and one trans- 
membrane domain in the COOH terminus, as judged by the 
hydropathy profiles calculated by the method of Kyte and 
Doolittle (33); (b) the proteins have no signal sequences; and 
(c) the possible N-glycosylation sites in all the proteins are 
located in the region between the first and second transmem- 
brane domains and/or between the third and fourth trans- 
membrane domains,  except in  TAPA-1. Furthermore,  the 
Cys-Cys-Gly sequence at positions 152 to 154 in DRAP27 
is conserved in all the proteins. These structural features and 
the Cys-Cys-Gly sequences are also found in all four RDS 
proteins.  In the  alignment of Fig.  7,  identical as  well  as 
chemically similar amino acids conserved in all proteins are 
distributed in all four putative transmembrane domains, with 
Table II.  Proteins with Significant Homology to DRAP27 
Length in  Local 
amino acids  homology 
% 
DRAP27  228  100.0 
CD9  228  99.1 
TAPA-1  236  44.2 
CO-029  237  31.7 
CD37  281  29.3 
CD53  219  26.2 
OX-44  219  30.7 
ME491/CD63  238  24.5 
SM23  218  25.2 
SJ23  218  23.3 
ME491/CD63  238  100.0 
h-RDS  346  19.0 
b-RDS  346  23.2 
r-RDS  346  22.1 
m-RDS  346  23.8 
Proteins  whose amino  acid sequence showed signifiant homology to that of 
DRAP27  (standard deviation >6) were screened from data banks  (GenBank 
release 68, EMBL release 27, and SWISS PROT release 17) using the method 
of Pearson and Lipman (49). The RDS proteins showed significant homology 
to ME491/CD63 antigen but not to DRAP27 under these criteria. The local ho- 
mology between ME491/CIMi3 and the RDS proteins  are also shown. 
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Figure  6.  Binding of t25I-labeled CRM197 to clone C15-2 cells, 
clone C-1 cells, and parental 3279-10 cells. (A) Cells (4  x  105/ 
sample) were incubated at 4~  for 8 h with binding medium (0.5 
ml)  containing  various  concentrations  of ~25I-labeled CRM197. 
Cells were then washed, and the radioactivity associated with the 
cells was determined. The data are expressed as specific binding. 
Nonspecific binding of ~25I-labeled CRM197 to C15-2 ceils, C-1 
cells, and 3279-10 cells was 10-16%, 20-26%, and 44-54% of the 
total binding, respectively. (B) Scatchard plot of the specific bind- 
ing of 12~I-labeled  CRM197 to C15-2 cells and C-1 cells. The lines 
were fitted by regression analysis. (e) clone C15-2 cells; (&) clone 
C-1 cells; (m) 3279-10 cells. 
the  greatest similarity in  the  three NH2-terminal putative 
transmembrane domains. In contrast, the long putative ex- 
tracellular domains between the third and fourth transmem- 
brane domains are highly divergent except for the Cys-Cys- 
Gly sequences. As the alignment of Fig. 7 was made by the 
maximum parsimony method of Hein (25), the phylogeny of 
these proteins was obtained simultaneously; that is shown in 
Fig.  8. 
Discussion 
In earlier studies, we showed that a mAb directed to a 27-kD 
membrane protein (DRAP27) inhibits the binding of DT to 
Vero cells and that DRAP27 associates with the DT receptor 
(DTR14.5) (28). We have cloned and sequenced the cDNA 
encoding DRAP27 and found that this protein is the monkey 
homologue of CD9  antigen,  differing at  only two  amino 
acids. Moreover, four independently isolated mouse mAbs 
to CD9 antigen react with Vero cells and inhibit the binding 
of DT,  and the CD9 antibody recognizes a 27-kD protein 
identical to DRAP27 when Western blotting analysis is per- 
formed using Vero cell membranes. 
The anti-DRAP27 mAb, 007,  inhibits the toxicity of DT 
to human cell lines, but it does not inhibit the cytotoxicity 
of DT to the human-mouse hybrid cell 3279-10 in which 
CD9 antigen is not expressed. These results confirm that the 
inhibitory effect of antibody 007 is due to the binding of the 
antibody to DRAP27/CD9 antigen. Although the direct evi- 
dence has not been obtained, we postulate that CD9 antigen 
associates with DT receptor molecules in human cell lines 
just as DRAP27 does in monkey Vero cells. 
We previously suggested that DRAP27 may play a role in 
the binding and/or in later steps of DT entry into cells be- 
cause of the correlation between the sensitivity of cell lines 
to DT and the number of DRAP27 molecules on the surface 
of the cells (28). We show here direct evidence by transfec- 
tion of the cDNA encoding DRAP27 into human-mouse hy- 
brid cell line lacking the gene for CD9 antigen. Expression 
of DRAP27 results in increased binding of DT and enhanced 
DT sensitivity. Thus, it is clear that DRAP27 has a positive 
effect on DT binding and intoxication. In contrast, transfec- 
tion of the cDNA for DRAP27 into mouse cell lines did not 
increase DT binding or sensitivity. Therefore, it is also clear 
that the DRAP27/CD9 antigen itself is not a DT receptor. 
Previous studies using human-mouse hybrid cells showed 
that a gene responsible for DT sensitivity is located on hu- 
man chromosome 5  (20).  The monochromosomal hybrid 
containing only human chromosome 5  is sensitive to DT. 
Significant binding of ~2~I-labeled DT is observed, but the 
DT sensitivity and the amount of DT bound are lower than 
with human cells (3). These results are consistent with our 
present results. The gene responsible for DT sensitivity on 
chromosome 5 is likely to encode the DT receptor. The gene 
for CD9 antigen located on human chromosome 12 is proba- 
bly also required for full expression of DT sensitivity in the 
mouse-human hybrid. Recently, DT-sensitive cells were iso- 
lated from toxin-resistant L,k- cells transfected with geno- 
mic DNA from Veto cells. Interestingly, the sensitivity of 
these cells was lower than that of Veto cells (46). This lower 
sensitivity to DT might be due to the absence of DRAP27. 
How does DRAP27/CD9 enhance the binding of DT to 
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Figure 7. Alignment of the amino acid 
sequences of DRAP27 and the homol- 
ogous  transmembrane  proteins.  The 
amino acid  sequences of  10 proteins 
screened by the method of Pearson and 
Lipman  (49) are aligned  through  the 
maximum  parsimony  method  (25). 
Amino acids conserved in all the pro- 
teins are indicated in the bottom line 
labeled  CONSENSUS,  and  gaps  are 
indicated as -. Identical and physico- 
chemically  homologous  amino  acids 
found  at  the  same position  in  more 
than  eight  proteins  are  enclosed  in 
hatched  boxes;  the  combinations  of 
chemically  homologous  amino  acids 
are as follows: I, L,  V,  M;  F, W, Y; 
A,  G;  D,  E;  H,  K,  R;  S,  T;  N,  Q. 
TMI,  TM2,  TM3,  TM4  indicate  the 
putative transmembrane domains pre- 
dicted  by  Kyte-Doolittle  hydropathy 
analysis  with a  window width  of  15 
(33).  N-linked glycosylation sites are 
underlined. 
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Figure 8. Phylogenic relationship 
of the amino acid sequences of 
the new family of transmembrane 
proteins.  The  relationship  be- 
tween  ME491/CD63  and  RDS 
proteins  is  indicated  by  dotted 
lines, but the distances are not ac- 
curate because RDS proteins were 
not aligned with other proteins. 
The length of the solid lines cor- 
responds to the relative distances 
calculated by the maximum par- 
simony method of Hein (25). 
cells? Binding studies  with  *2~I-labeled CRM197  revealed 
that cells expressing DRAP27 have more DT binding sites 
than the parental 3279-10 cells. Therefore, we are consider- 
ing the following possibilities: (a) DRAP27 may stabilize the 
DTR14.5 molecule by associating with it on the cell surface, 
resulting in an increase in DT receptor molecules on the cell 
surface,  or  (b)  DRAP27  may  facilitate  the  transport  of 
DTR14.5 molecules to the cell surface. Efficient transport 
would result in an increase in the number of receptors. How- 
ever, because the Ka value of parental 3279-10 ceils for DT 
could not be determined, we cannot eliminate the possibility 
that DRAP27 may also modulate the affinity of  the DT recep- 
tor. Indeed, Scatchard plot analysis showed that C-1  cells, 
which have fewer DRAP27 molecules than C15-2 cells, had 
a lower Ka. A change in the affinity of cells to DT might re- 
sult from association of DRAP27 with DTR14.5, resulting in 
a conformational change in DTRI4.5 that increases affinity. 
Or, DRAP27 may have a low affinity to DT that cannot be 
demonstrated in the absence of DTR14.5. When DRAP27 
combines with DT receptor, DT may bind more strongly to 
the complex. 
The toxicity of DT for Vero cells is inhibited by some an- 
ion transport inhibitors (53), suggesting a role of anion chan- 
nels in DT intoxication. The structure of  DRAP27/CD9 anti- 
gen, with four putative transmembrane domains,  suggests 
that this protein may form a channellike structure, as CD20 
antigen forms the Ca  2+ channel (Tedder, T. F., L. J. Zhou, 
P.  D. Bell, R. A. Frizell, and J.  K. Bubien.  1990. J.  Cell. 
Biochem. Suppl.  14D:195 Abstr.; 61). IfDRAP27/CD9 anti- 
gen forms such a channel, it may be involved in the translo- 
cation step of DT as well as the binding step. 
What is the physiological function of CD9 antigen? It may 
play an important role in platelet activation. Most mAbs to 
CD9  antigen cause the activation of platelets and induce 
aggregation in the presence of calcium (13, 22, 23, 26, 29, 
50). Association of CD9 antigen with the platelet glycopro- 
tein IIb-IIIa complex has been demonstrated (57).  Activa- 
tion of platelets by CD9  antibody is  mediated b  the  Fc-/ 
receptor (66), which may indicate that these molecules are 
involved in transmembrane signal transduction. CD9 anti- 
gen is also expressed in a wide variety of hemopoietic and 
nonhemopoietic tissues (12).  CD9 antigen is expressed on 
pre-B cells and leukemia cells derived from cells of  this stage 
(30). Although CD9 antigen is not expressed on mature cir- 
culating B and T cells, the expression is induced by stimula- 
tion with mitogen or alloantigen. CD9 antibody labels vari- 
ous tissues including vascular smooth muscle cells, cardiac 
muscle cells, and the distal tubules of the kidney. The wide- 
spread distribution of CD9 antigen suggests that it plays a 
fundamental role.  The number of molecules of DRAP27/ 
CD9 antigen is much greater than the number of DTR14.5 
molecules on Vero cells or human cells (28). This suggests 
that a large fraction of CD9 antigen is not associated with 
the DT receptor. CD9 antigen may serve as a positive effec- 
tor protein in a variety of cell surface receptor systems. 
We found a total of 13 related proteins using the homology 
search procedure of Pearson and Lipman (49). These pro- 
teins have a set of common structural motifs, i.e., four trans- 
membrane domains, a relatively long extracellular domain 
between the third and the fourth transmembrane domains, 
and no signal  sequences.  These proteins constitute a  new 
family of transmembrane proteins,  of which  subsets  have 
been recognized previously (34, 47).  The proteins in this 
family seem  to have diverged from  a  common ancestral 
protein. 
The regions from the first to the third putative transmem- 
brane domains are well conserved among all members of this 
family except the RDS, suggesting that these domains play 
important roles in the structure and/or function of these pro- 
teins. Although the putative extracellular domains between 
the  third  and  fourth  transmembrane  domains  are  highly 
divergent, the Cys-Cys-Gly sequences in this region are con- 
served in all the proteins. 
TAPA-1 was initially defined as the target of an antipro- 
liferative antibody in human lymphoid cells, but the antibody 
reacts with a variety of lymphoid and nonlymphoid human 
Mitamura et al. Diphtheria Toxin Receptor-associated Protein  1397 cell lines (47). An interesting feature of TAPA-1 is that this 
molecule associates with the 16-kD Leu-13 antigen (60), as 
DRAP27/CD9  antigen associates with DTR14.5.  The wild- 
type  RDS  gene  is expressed  exclusively  in photoreceptor 
cells. It has been proposed to serve as an adhesion molecule 
for stabilization of the outer segment discs (64). 
In conclusion, DRAP27/CD9  antigen associates with the 
DT receptor. It enhances DT binding activity and sensitivity, 
at least by increasing the number of DT receptors on the cell 
surface. As the physiological function of CD9 antigen in ceils 
is not clear, studies on the role of CD9 antigen in the DT 
receptor system may help to elucidate the general function 
of CD9 antigen and related proteins. 
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